Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VLA 15

Next Previous
Drug Profile

VLA 15

Alternative Names: Borrelia vaccine - GlaxoSmithKline/Valneva; Lyme borreliosis vaccine - GlaxoSmithKline/Valneva; Lyme-borreliosis-vaccine-Valneva; Lyme-disease-vaccine-GlaxoSmithKline/Valneva; Lyme-disease-vaccine-Valneva; PF-07307405; VLA 15

Latest Information Update: 03 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intercell
  • Developer Pfizer; Valneva
  • Class Bacterial vaccines; Lyme disease vaccines; Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Lyme disease

Most Recent Events

  • 30 Mar 2026 Pfizer plans a phase III trial for Lyme Disease (Prevention, In children, In adolescents, In adults, In the elderly) in USA (Intramuscular, Injection) in April 2026 (NCT07500506)
  • 23 Mar 2026 Immunogenicity and adverse events data from phase III VALOR trial in Lyme disease released by Pfizer
  • 03 Feb 2026 VLA 15 is still in phase III trials in Lyme disease (In adolescents, In adults, In children, Prevention, In the elderly) in Poland, Netherlands, Germany, Finland, Canada, Sweden and USA (IM) (NCT05477524)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top